145 related articles for article (PubMed ID: 23662001)
1. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison.
Inamoto T; Ubai T; Nishida T; Fujisue Y; Katsuoka Y; Azuma H
Urol Ann; 2013 Jan; 5(1):7-12. PubMed ID: 23662001
[TBL] [Abstract][Full Text] [Related]
2. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study.
Tachibana T; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Maeyama R; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Urol Int; 2023; 107(3):230-238. PubMed ID: 36646046
[TBL] [Abstract][Full Text] [Related]
4. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
Sengiku A; Ito M; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
J Urol; 2013 Jul; 190(1):50-4. PubMed ID: 23376145
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
6. Impact of maintenance therapy using a half dose of the bacillus Calmette-Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study.
Koguchi D; Matsumoto K; Hirayama T; Moroo S; Kobayashi M; Katsumata H; Ikeda M; Iwamura M
BMC Urol; 2020 Dec; 20(1):194. PubMed ID: 33298034
[TBL] [Abstract][Full Text] [Related]
7. Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients With T1 High Grade Bladder Cancer.
Yu SH; Wang CY; Wang SS; Li JR; Hung SC
Anticancer Res; 2024 Mar; 44(3):1299-1307. PubMed ID: 38423631
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
10. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.
Steinberg RL; Brooks NA; Thomas LJ; Mott SL; O'Donnell MA
Urol Oncol; 2017 May; 35(5):201-207. PubMed ID: 28041998
[TBL] [Abstract][Full Text] [Related]
12. Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
Urol Oncol; 2018 Jun; 36(6):306.e1-306.e8. PubMed ID: 29530465
[TBL] [Abstract][Full Text] [Related]
13. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
14. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
15. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
17. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
18. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
19. Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin.
Tozawa K; Okamura T; Yamada Y; Hayashi Y; Sasaki S; Kohri K
Asian Pac J Cancer Prev; 2000; 1(3):217-220. PubMed ID: 12718668
[TBL] [Abstract][Full Text] [Related]
20. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
